Lataa...
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
OBJECTIVES: To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy. METHODS: This is a phase III, randomised, double-blind, parallel-group, multicent...
Tallennettuna:
Julkaisussa: | Ann Rheum Dis |
---|---|
Päätekijät: | , , , , , , , , , , , , |
Aineistotyyppi: | Artigo |
Kieli: | Inglês |
Julkaistu: |
BMJ Publishing Group
2017
|
Aiheet: | |
Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5264222/ https://ncbi.nlm.nih.gov/pubmed/26150601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-207588 |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|